HC Wainwright Estimates Legend Biotech FY2026 Earnings

Legend Biotech Co. (NASDAQ:LEGN) – Equities researchers at HC Wainwright issued their FY2026 earnings per share estimates for Legend Biotech in a research note issued on Wednesday, May 14th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of $2.18 per share for the year. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share.

LEGN has been the topic of a number of other research reports. Royal Bank of Canada restated an “outperform” rating and issued a $84.00 target price on shares of Legend Biotech in a research note on Tuesday, April 22nd. Truist Financial decreased their target price on Legend Biotech from $88.00 to $71.00 and set a “buy” rating for the company in a research note on Wednesday. Guggenheim reaffirmed a “neutral” rating on shares of Legend Biotech in a report on Wednesday, March 12th. Morgan Stanley dropped their target price on Legend Biotech from $82.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, March 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $55.00 price target on shares of Legend Biotech in a research report on Wednesday. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $74.73.

Legend Biotech Stock Up 0.3%

NASDAQ:LEGN opened at $27.78 on Friday. The business’s fifty day moving average price is $33.47 and its 200 day moving average price is $35.85. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. Legend Biotech has a 1-year low of $27.34 and a 1-year high of $60.87. The firm has a market capitalization of $5.10 billion, a price-to-earnings ratio of -29.24 and a beta of 0.20.

Legend Biotech (NASDAQ:LEGN) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.33. The firm had revenue of $195.05 million for the quarter, compared to analyst estimates of $190.83 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LEGN. Exane Asset Management acquired a new stake in Legend Biotech during the 4th quarter worth $2,284,000. Matthews International Capital Management LLC increased its position in shares of Legend Biotech by 14.9% in the fourth quarter. Matthews International Capital Management LLC now owns 1,185,516 shares of the company’s stock valued at $38,577,000 after acquiring an additional 153,665 shares during the last quarter. Asset Management One Co. Ltd. increased its position in shares of Legend Biotech by 26.1% in the fourth quarter. Asset Management One Co. Ltd. now owns 11,085 shares of the company’s stock valued at $360,000 after acquiring an additional 2,297 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Legend Biotech by 196.1% in the fourth quarter. New York State Common Retirement Fund now owns 59,276 shares of the company’s stock valued at $1,929,000 after acquiring an additional 39,256 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Legend Biotech by 1,513.3% during the fourth quarter. Blue Trust Inc. now owns 5,840 shares of the company’s stock worth $190,000 after purchasing an additional 5,478 shares during the period. 70.89% of the stock is currently owned by institutional investors.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).